BC PharmaCare is looking for your input on canakinumab for the treatment of systemic juvenile idiopathic arthritis (sJIA)
Canakinumab (Ilaris®) is now being considered for coverage under the British Columbia Ministry of Health’s PharmaCare program. By filling out a questionnaire on a website called Your Voice, you can provide feedback about canakinumab for the treatment of sJIA.
You can give input if you are a B.C. resident and have sJIA, a caregiver to someone with sJIA, or if your group represents people who live with sJIA.
The input is reviewed by the Drug Benefit Council, which then gives recommendations on whether a medication should be covered, and how, by BC PharmaCare. BC PharmaCare then makes a decision based on those recommendations and available resources. Policies and plans already in place also factor in the decision making process. Continue reading →
Call for patient input on SEB etanercept for rheumatoid arthritis (RA) and ankylosing spondylitis (AS). Do you have RA or AS or care for someone who does? We need your valuable input.
Health Canada defines subsequent entry biologics (SEBs) as biologic medicines that are similar to, and would enter the market after an approved innovator biologic (such as Enbrel®).
Unlike the more common small-molecule drugs, biologics generally exhibit high molecular complexity, and are sensitive to changes in manufacturing practices. SEBs are not identical to their innovator products because their chemical characteristics cannot be precisely duplicated during the manufacturing process. Therefore, SEBs may have unique efficacy, immunogenicity, and safety profiles that are different from their innovator products.
The Common Drug Review (CDR) is currently welcoming patients and their caregivers to provide input to patient organizations on the manufacturer’s submission for SEB etanercept for the treatment of rheumatoid arthritis or ankylosing spondylitis. The innovator biologic, or reference product, is etanercept (Enbrel®). Continue reading →
Good news/bad news for Canadians living with arthritis, depending on where they live
Arthritis Consumer Experts (ACE) has released its Ninth Annual JointHealth™ Arthritis Medications Report Card with a clear message to the federal and provincial governments in Canada: Reimbursement access to arthritis medications has improved in many Canadian provinces, however, disappointing inequities remain in patient/physician choice and patient access to reimbursement for the medication prescribed for them by their rheumatologist.
“Thanks to the advocacy efforts of people living with arthritis and their rheumatologists, progress has been made in many Canadian provinces. We encourage the federal and provincial governments to maintain their commitment to the estimated 600,000 Canadians living with a type of autoimmune arthritis – rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis and juvenile idiopathic arthritis – and their right to choose with their healthcare team the therapy best suited to their disease biology, which is distinctly different from patient to patient,” said Cheryl Koehn, Founder and President, Arthritis Consumer Experts. Continue reading →
This forum will help patients with ankylosing spondylitis and psoriatic arthritis and their family. Register now for free! The Spondyloarthritis Research Consortium of Canada and the Canadian Spondylitis Association, in collaboration with The Arthritis Society, would like to invite you to register for free to the 2016 Spondyloarthritis Patient Forum. The forum aims to help patients living with ankylosing spondylitis (AS) and psoriatic arthritis (PsA) and their family. Light refreshments will be provided.
Here are the event details:
Date: Saturday, April 30, 2016 Location: Sheraton Vancouver Wall Centre, Junior Ballroom CD
1088 Burrard Street, Vancouver Time: 3:30pm-7:00pm Cost: Free
Please note pre-registration is required. Seats are limited. You can register: Continue reading →
Do you have ankylosing spondylitis (AS) or psoriatic arthritis (PsA) or care for someone who does? We need your valuable input.
The Common Drug Review (CDR) is currently welcoming patients and their caregivers to provide input to patient organizations on the manufacturer’s submission for secukinumab (Cosentyx®) for the treatment of ankylosing spondylitis or psoriatic arthritis. Secukinumab is a fully human monoclonal antibody that targets IL-17A, a protein central to the development of inflammatory diseases. It is given by an injection.
The CDR is part of the Canadian Agency for Drugs and Technologies in Health (CADTH). The CDR conducts objective, rigorous reviews of the clinical and cost effectiveness of drugs, and provides formulary listing recommendations to the publicly funded drug plans in Canada (except Quebec).
To help them make their recommendations, the CDR accepts input from patient groups, like Arthritis Consumer Experts (ACE). We are calling for input from our members, subscribers and their family members who have ankylosing spondylitis or psoriatic arthritis. Caregivers are also invited to provide input.